Tuesday, August 29, 2023
Taiho Pharmaceutical and Phost’in Therapeutics have entered into an option and licence agreement that outlines their collaboration regarding the development and commercialisation of a novel compound named PhOx430.
Under the terms of this agreement, Taiho Pharmaceutical has acquired option rights to in-licence PhOx430 and other undisclosed compounds. In exchange for these rights, Taiho Pharmaceutical has made an upfront payment to Phost’in. The primary focus of this partnership is to exclusively develop and market these compounds in Japan and specific Asian territories (excluding China).
The strategic collaboration between Taiho Pharmaceutical and Phost’in aims to advance the development of innovative and valuable pharmaceuticals to address unmet medical needs.
PhOx430 is currently in the Phase I/II stages of clinical evaluation in Europe as part of the PhAST trial. This trial is assessing its efficacy and safety in patients with advanced solid tumours.
PhOx430 is the flagship programme from Phost’in's Phost’ScreenTM platform, which leverages proprietary chemical libraries and advanced screening technologies to identify and develop selective N-glycosylation inhibitors. These inhibitors have the potential to be utilised in treating a range of serious conditions, including cancer and other immunoinflammatory diseases.
